Of note, since study completion, two individuals newly developed RA, but at the time of stool sampling (~2 years before), they were assigned to the control group (seronegative, with no clinically significant symptoms—they later developed ACPA-negative RA). The gene discussed is PRTN3; the disease is rheumatoid arthritis.